Part of Molecular Diagnostics Europe – 4-7 April, 2016, Sheraton Lisboa, Lisbon, Portugal
Circulating tumour DNA has grown in popularity given its ability to detect minimal residual disease and monitor treatment. Regardless of growing proof of its utility, much needs to be done to make liquid biopsy clinically useful. With this in mind, Cambridge Healthtech Institute’s Second Annual Circulating Cell-Free DNA will critically examine circulating biomarkers for use in guiding molecular analyses. This year’s event will place emphasis on early detection, clinical validation of assay sensitivity and specificity, and working with various sample types. Circulating tumour DNA for patient stratification and outcome prediction will be addressed as well as logistical considerations for translation.
Circulating Cell-Free DNA (April 6-7) immediately follows CHI’s Circulating Tumour Cells (April 5-6) event, allowing attendees to continue examining challenges and solutions in circulating biomarkers. Overall, these two events will provide attendees with concrete ideas to ensure success in the clinic.